The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- AnGes MG Changes Development Strategy for NF-κB Decoy Oligo
January 5, 2015
- Shin Nippon Biomedical Laboratories to Tie Up with US CRO for Clinical Development Services
January 5, 2015
- Opdivo Receives Accelerated Approval in US for Malignant Melanoma: BMS
January 5, 2015
- Bayer Yakuhin Files PAH Drug Iloprost for Approval
December 26, 2014
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
- Chugai Wins First Round in Patent Infringement Lawsuit for Oxarol Ointment
December 26, 2014
- Otsuka Obtains Rights from ARIAD to Develop, Commercialize Ponatinib in Japan and Other Asian Countries
December 26, 2014
- Taiho Completes NDA Submission for Lonsurf in US
December 26, 2014
- Takeda Files NDA for Glatiramer Licensed from Teva for Relapse Prevention of Multiple Sclerosis
December 26, 2014
- Astellas Expands Scope of Collaboration with Cytokinetics in Skeletal Muscular Disease Field
December 25, 2014
- NDA for Selexipag Filed in US by Actelion: Nippon Shinyaku
December 25, 2014
- Fujifilm Completes Acquisition of Kalon Biotherapeutics
December 24, 2014
- AZ, Quintiles Create New Drug Development Team, Fusing Pharma’s Expertise with CRO’s Knowhow
December 24, 2014
- Ono Licenses Exclusive Worldwide Rights for BTK Inhibitor to Gilead Excluding East and South East Asia
December 22, 2014
- Chugai, Yakult File Xeloda, Elplat for Postoperative Adjuvant Chemotherapy for Gastric Cancer
December 22, 2014
- Poteligeo Now Indicated for Chemotherapy-Naïve CCR4-Positive ATL: Kyowa Kirin
December 19, 2014
- Taiho’s Abraxane Gets Nod for Unresectable Pancreatic Cancer
December 19, 2014
- Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
- MTPC Reorganizing Its US Affiliates to Accelerate Operation Expansion
December 19, 2014
- Fujifilm Holdings Makes J-TEC Its Consolidated Subsidiary
December 19, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…